Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | ERBB3 | P21860 | 6/20 | 0.54 |
| ▸ | TEK | Q02763 | 6/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 6/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | EIF2AK3 | Q9NZJ5 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939880 | 0.93 | EGFR (0.55) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1940300 | 0.92 | EGFR (0.56) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4079475 | 0.91 | NTRK1 (0.49) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1941276 | 0.90 | EGFR (0.57) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1940933 | 0.90 | PDGFRB (0.63) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1941569 | 0.89 | EGFR (0.52) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1940803 | 0.89 | EGFR (0.53) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1939905 | 0.88 | EGFR (0.51) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1940888 | 0.88 | EIF2AK3 (0.51) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1939522 | 0.88 | EIF2AK3 (0.58) | EGFRERBB2ERBB3TEKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| CN-1726218-A | Pyrrolopyrimidine derivatives | PFIZER PROD INC (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | EGFR 2758/4885ERBB2 2738/4885ERBB3 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.